Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBB 515 BS vs Pravastatin in Hyperlipemic Healthy Males
NCT02266485Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1998
- Primary completion
- Sep 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIBB 515 in hyperlipidemia (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage changes in total-cholesterol, Percentage changes in low density lipoprotein (LDL) - cholesterol and 9 more. Started Jul 1998; status: completed.
02
Drugs
BIBB 515
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02266485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266485.